CPH Stock Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
Cipher Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$2.30|
|52 Week High||CA$2.80|
|52 Week Low||CA$1.43|
|1 Month Change||-3.36%|
|3 Month Change||-3.77%|
|1 Year Change||49.35%|
|3 Year Change||75.57%|
|5 Year Change||-59.65%|
|Change since IPO||-37.84%|
Recent News & Updates
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|CPH||CA Pharmaceuticals||CA Market|
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -70.9% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned -4.1% over the past year.
|CPH Average Weekly Movement||5.4%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||10.0%|
|10% most volatile stocks in CA Market||17.3%|
|10% least volatile stocks in CA Market||4.4%|
Stable Share Price: CPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CPH's weekly volatility (5%) has been stable over the past year.
About the Company
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company’s licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Cipher Pharmaceuticals Fundamentals Summary
|CPH fundamental statistics|
Is CPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPH income statement (TTM)|
|Cost of Revenue||US$3.89m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.34|
|Net Profit Margin||39.10%|
How did CPH perform over the long term?See historical performance and comparison
Is CPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CPH?
Other financial metrics that can be useful for relative valuation.
|What is CPH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CPH's PE Ratio compare to its peers?
|CPH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: CPH is good value based on its Price-To-Earnings Ratio (5.3x) compared to the peer average (26.2x).
Price to Earnings Ratio vs Industry
How does CPH's PE Ratio compare vs other companies in the Pharmaceuticals Industry?
Price-To-Earnings vs Industry: CPH is good value based on its Price-To-Earnings Ratio (5.3x) compared to the Canadian Pharmaceuticals industry average (8.2x)
Price to Earnings Ratio vs Fair Ratio
What is CPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||5.3x|
|Fair PE Ratio||23.1x|
Price-To-Earnings vs Fair Ratio: CPH is good value based on its Price-To-Earnings Ratio (5.3x) compared to the estimated Fair Price-To-Earnings Ratio (23.1x).
Share Price vs Fair Value
What is the Fair Price of CPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CPH (CA$2.3) is trading below our estimate of fair value (CA$15.88)
Significantly Below Fair Value: CPH is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: CPH is good value based on its PEG Ratio (0.7x)
Discover undervalued companies
How is Cipher Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPH's forecast earnings growth (7.9% per year) is above the savings rate (1.6%).
Earnings vs Market: CPH's earnings (7.9% per year) are forecast to grow slower than the Canadian market (8.3% per year).
High Growth Earnings: CPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: CPH's revenue (4% per year) is forecast to grow slower than the Canadian market (7.3% per year).
High Growth Revenue: CPH's revenue (4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Cipher Pharmaceuticals performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPH has high quality earnings.
Growing Profit Margin: CPH's current net profit margins (39.1%) are higher than last year (15.4%).
Past Earnings Growth Analysis
Earnings Trend: CPH's earnings have declined by 0.2% per year over the past 5 years.
Accelerating Growth: CPH's earnings growth over the past year (163.8%) exceeds its 5-year average (-0.2% per year).
Earnings vs Industry: CPH earnings growth over the past year (163.8%) exceeded the Pharmaceuticals industry 118.1%.
Return on Equity
High ROE: CPH's Return on Equity (21.2%) is considered high.
Discover strong past performing companies
How is Cipher Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CPH's short term assets ($31.8M) exceed its short term liabilities ($13.2M).
Long Term Liabilities: CPH's short term assets ($31.8M) exceed its long term liabilities ($467.0K).
Debt to Equity History and Analysis
Debt Level: CPH is debt free.
Reducing Debt: CPH has no debt compared to 5 years ago when its debt to equity ratio was 257.3%.
Debt Coverage: CPH has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CPH has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Cipher Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CPH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and its Interim Chief Executive Officer since July 29, 2019, served as its President. Mr. Mu...
Experienced Management: CPH's management team is considered experienced (2.9 years average tenure).
Experienced Board: CPH's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cipher Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Cipher Pharmaceuticals Inc.
- Ticker: CPH
- Exchange: TSX
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$58.491m
- Shares outstanding: 25.43m
- Website: https://www.cipherpharma.com
Number of Employees
- Cipher Pharmaceuticals Inc.
- 209 Oak Park Boulevard
- Suite 501
- L6H 0M2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.